On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise. Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $90...
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 3.9%, w...
Johnson & Johnson (JNJ 1.57%) is one of the world's largest healthcare companies by market capitalization. The drugmaker has diversified operations, generating consistent revenue and profits.
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.